Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Illumina Files...

    Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-02T10:15:37+05:30  |  Updated On 2 March 2020 12:36 PM IST
    Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.

    San Diego: Illumina, Inc. today announced that it has filed a patent infringement suit relating to BGI's "CoolMPS" sequencing products. The complaint was filed against BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas, Inc. and Complete Genomics Inc. in the United States District Court for the Northern District of California alleging infringement of three patents: US Patent Nos. 7,541,444; 7,771,973; and 10,480,025. The complaint seeks, among other things, damages, injunctive relief and attorney fees. The patents cover Illumina's proprietary sequencing-by-synthesis chemistry.

    "BGI has brazenly copied Illumina's proprietary sequencing chemistry. Illumina's patent portfolio reflects the incredible innovation of Illumina's employees and the investment of hundreds of millions of dollars that Illumina spends annually on research and development," said Charles Dadswell, SVP and General Counsel for Illumina. "We will continue to monitor and defend our intellectual property by appropriate enforcement when our patents are infringed."

    Related patent suits are pending in Denmark, Germany, Sweden, Switzerland, Turkey, the UK and the U.S. Counterparts to these newly asserted patents have been upheld by the U.S. Patent Trial and Appeal Board and the European Patent Office over challenges filed by BGI, Complete Genomics and others.

    Read also: FTC seeks to block Illumina from buying PacBio

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

    Medical Dialogues has previously reported that Illumina Inc on Thursday agreed to terminate the $1.2 billion deal to buy smaller rival Pacific Biosciences of California Inc, weeks after the U.S. competition watchdog filed a complaint to block the purchase.

    Read also: Pacific Biosciences, Illumina cancel USD 1.2 billion deal

    illuminabgi-genomicsbgi-americasmgi-tech

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok